IntraBio Inc., a global biopharmaceutical company focused on developing and commercializing therapies for neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
Stock Surges Following Positive Clinical UpdateShares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the ...
Shares of Design Therapeutics jumped after the company reported positive data from a study of its DT-216P2 drug for Friedreich ataxia, a neuromuscular disease. The stock rose 10% to $15.85 in ...
Design Therapeutics Inc. DSGN stock surged during the premarket session on Monday. The move came after the company reported ...
Rare conditions can be daunting, terrifying and isolating. For the people and families affected by them, the search for a ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 ...
Researchers have uncovered a fundamental rule that governs how genes are physically arranged inside the cell nucleus, and how ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing ...
Investor's Business Daily on MSN
This biotech leader ran up as much as 18% — and then lost it all
Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost ...
Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results